CoChat

Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

Open access

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cocoa extract is a source of flavanols that favorably influence vascular risk factors in small and short-term trials, yet effects on clinical cardiovascular events are untested. OBJECTIVES: We examined whether cocoa extract supplementation decreases total cardiovascular disease (CVD) among older adults. METHODS: We conducted a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of cocoa extract supplementation and multivitamins for prevention of CVD and cancer among 21,442 US adults (12,666 women aged ≥65 y and 8776 men aged ≥60 y), free of major CVD and recently diagnosed cancer. The intervention phase was June 2015 through December 2020. This article reports on the cocoa extract intervention. Participants were randomly assigned to a cocoa extract supplement [500 mg flavanols/d, including 80 mg (-)-epicatechin] or placebo. The primary outcome was a composite of confirmed incident total cardiovascular events, including myocardial infarction (MI), stroke, coronary revascularization, cardiovascular death, carotid artery disease, peripheral artery surgery, and unstable angina. RESULTS: During a median follow-up of 3.6 y, 410 participants taking cocoa extract and 456 taking placebo had confirmed total cardiovascular events (HR: 0.90; 95% CI: 0.78, 1.02; P = 0.11). For secondary endpoints, HRs were 0.73 (95% CI: 0.54, 0.98) for CVD death, 0.87 (95% CI: 0.66, 1.16) for MI, 0.91 (95% CI: 0.70, 1.17) for stroke, 0.95 (95% CI: 0.77, 1.17) for coronary revascularization, neutral for other individual cardiovascular endpoints, and 0.89 (95% CI: 0.77, 1.03) for all-cause mortality. Per-protocol analyses censoring follow-up at nonadherence supported a lower risk of total cardiovascular events (HR: 0.85; 95% CI: 0.72, 0.99). There were no safety concerns. CONCLUSIONS: Cocoa extract supplementation did not significantly reduce total cardiovascular events among older adults but reduced CVD death by 27%. Potential reductions in total cardiovascular events were supported in per-protocol analyses. Additional research is warranted to clarify whether cocoa extract may reduce clinical cardiovascular events. This trial is registered at www.clinicaltrials.gov as NCT02422745.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ajcn/nqac055

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Screening, randomization, and follow-up of the participants. 1Eligibility was determined by medical history, age, and willingness to forego personal use of cocoa extract and multivitamin pills. 2Eligibility was determined by medical history, age, willingness to forego personal use of cocoa extract and multivitamin pills, caffeine sensitivity, and willingness to limit calcium and vitamin D supplement use. 3Included subjects who never completed the screening phase (n = 2914), eligibility could not be determined (n = 5), and enrollment goal already met (n = 55). 4Included subjects who never completed screening phase (n = 168) and enrollment goal already met (n = 54).
FIGURE 1 Screening, randomization, and follow-up of the participants. 1Eligibility was determined by medical history, age, and willingness to forego personal use of cocoa extract and multivitamin pills. 2Eligibility was determined by medical history, age, willingness to forego personal use of cocoa extract and multivitamin pills, caffeine sensitivity, and willingness to limit calcium and vitamin D supplement use. 3Included subjects who never completed the screening phase (n = 2914), eligibility could not be determined (n = 5), and enrollment goal already met (n = 55). 4Included subjects who never completed screening phase (n = 168) and enrollment goal already met (n = 54).CC BY · PubMed Central
FIGURE 2 HRs and 95% CIs1 for the primary and secondary CVD outcomes, according to randomized assignment, in intention-to-treat analyses. 1Summary statistics were from Cox regression models that stratified baseline hazard functions by multivitamin trial randomization group, age, sex, and recruitment cohort. CIs were not adjusted for multiple comparisons. 2This outcome was a composite of myocardial infarction, stroke, CVD death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery. 3This outcome was a composite of myocardial infarction, stroke, and CVD death. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.
FIGURE 2 HRs and 95% CIs1 for the primary and secondary CVD outcomes, according to randomized assignment, in intention-to-treat analyses. 1Summary statistics were from Cox regression models that stratified baseline hazard functions by multivitamin trial randomization group, age, sex, and recruitment cohort. CIs were not adjusted for multiple comparisons. 2This outcome was a composite of myocardial infarction, stroke, CVD death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery. 3This outcome was a composite of myocardial infarction, stroke, and CVD death. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.CC BY · PubMed Central
FIGURE 3 Cumulative incidence rates of total cardiovascular events1 and CVD death, according to year of follow-up, in the cocoa extract group and placebo group. 1Primary outcome (left panel): a composite of myocardial infarction, stroke, CVD death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery. Secondary outcome (right panel): CVD death. Summary statistics were from Cox regression models that stratified baseline hazard functions by multivitamin trial randomization group, age, sex, and recruitment cohort (intention-to-treat analyses). P value was for the effect of randomization group, based on a stratified score (log-rank) test. Rates (%) were annualized. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.
FIGURE 3 Cumulative incidence rates of total cardiovascular events1 and CVD death, according to year of follow-up, in the cocoa extract group and placebo group. 1Primary outcome (left panel): a composite of myocardial infarction, stroke, CVD death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery. Secondary outcome (right panel): CVD death. Summary statistics were from Cox regression models that stratified baseline hazard functions by multivitamin trial randomization group, age, sex, and recruitment cohort (intention-to-treat analyses). P value was for the effect of randomization group, based on a stratified score (log-rank) test. Rates (%) were annualized. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.CC BY · PubMed Central
FIGURE 4 HRs and 95% CIs1 for the primary and secondary CVD outcomes, according to randomized assignment, where follow-up of noncompliant participants was censored. 1Summary statistics were from weighted Cox regression models that stratified baseline hazard functions by multivitamin trial randomization group, age, sex, and recruitment cohort, and used the robust sandwich estimator for variance. Time-dependent weights were calculated as the inverse probability of compliance, where probabilities were estimated from a Cox regression model with baseline hazard functions stratified by age, sex, recruitment source, multivitamin-trial arm and cocoa extract trial arm, and included baseline history of CVD and hypertension status (time-dependent) as covariates. CIs were not adjusted for multiple comparisons. 2A participant's follow-up was censored at the first time they reported having missed >8 d of cocoa extract study pills per month, took personal nonstudy cocoa extract, or did not respond to a semiannual questionnaire. 3Total cardiovascular event was a composite of myocardial infarction, stroke, CVD death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery. 4Major cardiovascular event was a composite of myocardial infarction, stroke, and CVD death. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.
FIGURE 4 HRs and 95% CIs1 for the primary and secondary CVD outcomes, according to randomized assignment, where follow-up of noncompliant participants was censored. 1Summary statistics were from weighted Cox regression models that stratified baseline hazard functions by multivitamin trial randomization group, age, sex, and recruitment cohort, and used the robust sandwich estimator for variance. Time-dependent weights were calculated as the inverse probability of compliance, where probabilities were estimated from a Cox regression model with baseline hazard functions stratified by age, sex, recruitment source, multivitamin-trial arm and cocoa extract trial arm, and included baseline history of CVD and hypertension status (time-dependent) as covariates. CIs were not adjusted for multiple comparisons. 2A participant's follow-up was censored at the first time they reported having missed >8 d of cocoa extract study pills per month, took personal nonstudy cocoa extract, or did not respond to a semiannual questionnaire. 3Total cardiovascular event was a composite of myocardial infarction, stroke, CVD death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery. 4Major cardiovascular event was a composite of myocardial infarction, stroke, and CVD death. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 207

Metadata

Authors
Sesso, H. D., Manson, J. E., Aragaki, A. K., Rist, P. M., Johnson, L. G., Friedenberg, G., Copeland, T., Clar, A., Mora, S., Moorthy, M. V., Sarkissian, A., Carrick, W. R., & Anderson, G. L.
Affiliations
  • Brigham and Women's Hospital (US)
  • Fred Hutch Cancer Center (US)
Corresponding author
Sesso, Howard D
Venue
The American Journal of Clinical Nutrition
Publisher
Elsevier BV
Published
2022-06
Volume
115
Issue
6
Pages
1490-1500
ISSN
0002-9165 (ISSN-L)
OpenAlex
W4221025812
Cited by
187
References
73
Citations by year
2026: 39 · 2025: 40 · 2024: 45 · 2023: 38 · 2022: 25
FWCI
19.36
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Clinical Nutrition (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • COSMOS (AG050657, AG071611, EY025623, HL157665)
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • U.S. Department of Health and Human Services (75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005)
  • Mars Edge
Topics
  • Health Sciences › Medicine › Biochemistry (medical) › Phytochemicals and Antioxidant Activities
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Food Chemistry and Fat Analysis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
cocoa flavanols, cocoa extract, epicatechin, cardiovascular disease prevention, cardiovascular events, myocardial infarction, stroke, coronary revascularization, cardiovascular mortality, older adults, multivitamin supplementation, cancer prevention, dietary supplementation, COSMOS trial, safety and tolerability, vascular risk factors, all-cause mortality, carotid artery disease, peripheral arterial disease
MeSH terms
Aged, Cacao, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Male, Myocardial Infarction, Neoplasms, Plant Extracts, Risk Factors, Vitamins, Dietary Supplements, Stroke, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. https://app.cochat.ai/papers/10.1093/ajcn/nqac055
The paper
Sesso, H. D., Manson, J. E., Aragaki, A. K., Rist, P. M., Johnson, L. G., Friedenberg, G., Copeland, T., Clar, A., Mora, S., Moorthy, M. V., Sarkissian, A., Carrick, W. R., & Anderson, G. L. (2022). Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. The American Journal of Clinical Nutrition. https://doi.org/10.1093/ajcn/nqac055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.